Annual report pursuant to Section 13 and 15(d)

Liquidity (Details Narrative)

v3.7.0.1
Liquidity (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2016
Jun. 30, 2016
Nov. 30, 2015
May 31, 2015
Dec. 31, 2015
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Accumulated deficit         $ 13,277,814   $ 33,276,489 $ 13,277,814
Gross proceeds from sale of stock             16,699,133 11,328,929
Stock issuance cost             260,179 509,215
Cash         12,338,275   14,992,257 $ 12,338,275
Cystic Fibrosis Foundation Therapeutics Inc [Member]                
Amount received on milestone payment $ 1,000,000   $ 1,250,000 $ 1,250,000 $ 1,250,000   $ 500,000  
Securities Purchase Agreement [Member] | Investors [Member]                
Aggregate common stock sold, shares   5,960,000       5,960,000    
Shares issued price per share   $ 2.50       $ 2.50    
Gross proceeds from sale of stock   $ 14,875,000       $ 14,875,000    
Stock issuance cost   $ 25,222            
Securities Purchase Agreement [Member] | Institutional And Accredited Investors [Member] | February 28, 2017 [Member]                
Aggregate common stock sold, shares             3,887,815  
Shares issued price per share             $ 7.00  
Gross proceeds from sale of stock             $ 27,214,705  
Stock issuance cost             $ 100,000